Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of NS-136 in Healthy Subjects
NCT06345703Phase 1Recruiting
- Sponsor
- NeuShen Therapeutics
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of NS-136 in schizophrenia and psychosis (14 arms), sponsored by NeuShen Therapeutics. Primary endpoints: Number of Participants with Treatment-Related Adverse Events and Main pharmacokinetic parameters. Started Apr 2024; status: recruiting.
02
Drugs
NS-136
03
Conditions
schizophreniapsychosis
Beyond the preview
Go deeper on NCT06345703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345703.